NovaCardia - Product Focus - Drugs in Development: "KW-3902: An Innovative Therapy for CHF
In-licensed from Kyowa Hakko in August 2003, KW-3902 (intravenous) is currently in Phase II development for Congestive Heart Failure (CHF) patients undergoing diuresis. This proprietary small molecule acts as an adenosine-A1 receptor antagonist. Current therapies for CHF introduce significant medical liabilities to patients, most notably the risk of worsening kidney function, a predictor of poor outcome. KW-3902, with its novel mechanism of action, has the potential to significantly improve the management of CHF, particularly in patients with renal dysfunction."
No comments:
Post a Comment